Tau protein as a potential predictive marker in epithelial ovarian cancer patients treated with paclitaxel/platinum first-line chemotherapy

Meta-analysis of gene expression profiles associated with histological classification and survival in 829 ovarian cancer samples

(2011) Tibor Fekete et al.   INTERNATIONAL JOURNAL OF CANCER

Paclitaxel and Carboplatin as Neoadjuvant Chemotherapy in Patients With Locally Advanced Breast Cancer: A Phase II Trial of the Hellenic Cooperative Oncology Group

(2010) Helen Gogas et al.   Clinical Breast Cancer

Doubling time of serum CA125 is an independent prognostic factor for survival in patients with ovarian cancer relapsing after first-line chemotherapy

(2010) Liz Y. Han et al.   EUROPEAN JOURNAL OF CANCER

Predictive and Prognostic Values of Tau and ERCC1 in Advanced Breast Cancer Patients Treated with Paclitaxel and Cisplatin

(2010) Y. Y. Shao et al.   JAPANESE JOURNAL OF CLINICAL ONCOLOGY

Evaluation of Microtubule-Associated Protein-Tau Expression As a Prognostic and Predictive Marker in the NSABP-B 28 Randomized Clinical Trial

(2009) Lajos Pusztai et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic factors of secondary cytoreductive surgery for patients with recurrent epithelial ovarian cancer

(2009) Jaeman Bae et al.   Journal of Gynecologic Oncology

Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial

(2008) George Pentheroudakis et al.   BREAST CANCER RESEARCH AND TREATMENT

Tau expression and efficacy of paclitaxel treatment in metastatic breast cancer

(2008) Satoru Tanaka et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY